TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Active patients who were enrolled in the MADIT-CRT IDE (NCT00180271)within the United States~Exclusion Criteria:~* Patients who are unable or unwilling to comply with the protocol requirements

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MADIT-CRT ICD (Type: None): None
- MADIT-CRT CRT-D (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent in the local language prior to any study-mandated procedure.~* Body mass index from 18.0 to 30.0 kg/m2 (inclusive) at Screening.~* Normal renal function confirmed by creatinine clearance ≥ 80 mL/min using Cockroft-Gault formula at Screening.~Exclusion Criteria:~* Known hypersensitivity to cimetidine, lucerastat, or drugs of the same class, or any of their excipients.~* History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed).~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment period A & B (Type: EXPERIMENTAL): Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Active rheumatoid arthritis~* Inadequate response to stably dosed methotrexate~Exclusion Criteria:~* Current therapy with any DMARD or biologic other than methotrexate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CP-690,550, 0mg (Type: PLACEBO_COMPARATOR): None
- CP-690,550, 10mg (Type: EXPERIMENTAL): None
- CP-690,550, 1mg (Type: EXPERIMENTAL): None
- CP-690,550, 3mg (Type: EXPERIMENTAL): None
- CP-690,550, 5mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation in HIV Youth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 8-25~* Documented HIV-1 infection~* On stable antiretroviral therapy for \> 3 months~* Cumulative antiretroviral therapy of at least 6 months~* 25(OH)D level \< 30 ng/ml at screening~Exclusion Criteria:~* \> 400 IU daily regular vitamin D intake~* Parathyroid/calcium disorders~* Active malignancy~* Pregnancy/intent to become pregnant/breastfeeding~* Chronic infectious/inflammatory conditions~* Creatinine clearance \< 50 ml/min~* Hemoglobin \< 9.0 g/dL~* Aspartate aminotransferase and alanine aminotransferase \> 2.5 upper limit of normal~* Diabetes requiring hypoglycemic agents~* Known coronary artery disease~* Inability to swallow pills

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- HIV + Young Adults (Type: ACTIVE_COMPARATOR): All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
- HIV - Controls (Type: ACTIVE_COMPARATOR): HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Georgia Institute of Technology (Georgia Tech) student~* 18 years old or older~* Living on campus in Georgia Tech dorms~Exclusion Criteria:~* Not a Georgia Tech student~* Under the age of 18~* Not living on campus in Georgia Tech dorms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): The subjects will choose their own mask and masking practices.
- Treatment Group (Type: EXPERIMENTAL): The treatment group will receive and use the focal mask.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Desmoteplase in Acute Ischemic Stroke (DIAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* scoring 4 to 20 on the National Institute of Health Stroke Scale (NIHSS)~* showing a perfusion-diffusion mismatch on MRI of 20 %~* enrolment within a 3 h to 9 h time window after symptom onset.~* 18-85 years of age~Exclusion Criteria:~* Participation in any interventional trial in the previous 30 days.~* Women in the childbearing age.~* Any history of intracranial hemorrhage, subarachnoid hemorrhage, neoplasm, arteriovenous malformation or aneurysm.~* Conditions that, according to the judgment of the investigator, might impose an additional risk to any individual stroke patient when receiving study medication (this applied to patients on platelet-function inhibitors as well).~* MRI exclusion criteria: Evidence of ICH, Evidence of SAH, Signs of extensive early infarction on DWI assessed by evidence of involvement of \>1/3 of the middle cerebral artery (MCA) territory. No perfusion deficit, Internal carotid artery (ICA) occlusion ipsilateral to stroke lesion without additional ipsilateral MCA, anterior cerebral artery (ACA) or posterior cerebral artery (PCA) occlusion. Any intracranial pathology that would interfere with the MRI assessment of acute ischemic stroke.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Desmoteplase 62.5 µg/kg BW i.v. bolus
- 2 (Type: ACTIVE_COMPARATOR): Desmoteplase 90 µg/kg BW i.v. bolus
- 3 (Type: ACTIVE_COMPARATOR): Desmoteplase 125 µg/kg BW i.v. bolus
- 4 (Type: PLACEBO_COMPARATOR): Placebo i.v. bolus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically verified adenocarcinoma of the rectum,~* resectable clinical stage II or III (IUCC TNM classification 2002);~* no prior radiotherapy and/or chemotherapy;~* World Health Organisation (WHO) performance status \< 2;~* age at diagnosis of 18 or older;~* and adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease).~Exclusion Criteria:~* A history of prior malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 24 months of age or younger at randomization (child must be randomized on or before his/her 24-month birthday) with a diagnosis of chronic lung disease (CLD) of prematurity requiring medical intervention/management (i.e., supplemental oxygen, bronchodilators, or diuretics) within 6 months before randomization~OR:~* 35 weeks gestational age or less at birth and 6 months of age or younger at randomization (children were to be randomized on or before his/her 6-month birthday)~Exclusion Criteria:~* Hospitalization at the time of randomization (unless discharge was anticipated within 10 days)~* Mechanical ventilation or other mechanical support (including continuous positive airways pressure \[CPAP\])~* Life expectancy \< 6 months~* Active RSV infection (a child with signs/symptoms of respiratory infection must have had negative RSV testing)~* Known renal impairment~* Known hepatic dysfunction~* Chronic seizure or evolving or unstable neurologic disorder~* Congenital heart disease \[CHD\] (children with uncomplicated CHD \[e.g., patent ductus arterious (PDA), small septal defect\] and children with complicated CHD that were currently anatomically and hemodynamically normal could be enrolled)~* Known immunodeficiency~* Mother with HIV infection (unless the child has been proven to be not infected)~* Known allergy to Ig products~* Receipt of palivizumab, RSV-IGIV, or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B IG, IVIG, VZIG) within 3 months prior to randomization~* Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)~* Previous receipt of RSV vaccines~* Participation in other investigational drug product studies

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- palivizumab (Type: ACTIVE_COMPARATOR): 15 mg/kg administered intramuscularly for 5 monthly doses
- motavizumab (MEDI-524) (Type: EXPERIMENTAL): 15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Proliferative Diabetic Retinopathy~* Best Corrected Visual Acuity (BCVA) in study eye of at least 20 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/400)~* Type 1 or type 2 diabetes under medical surveillance / with stabilized treatment~Exclusion Criteria:~* Proliferative vitreoretinopathy in study eye~* Clinically significant macular edema (CSME) in the study eye~* Clinically non significant macular edema (CNSME) that is likely to develop to CSME in the study eye~* Uncontrolled glaucoma in either eye~* Other protocol-specified conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab mono (Type: EXPERIMENTAL): Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
- PRP mono (Type: ACTIVE_COMPARATOR): Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
- Ranibizumab+PRP (Type: EXPERIMENTAL): Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients had residual aspirated specimens for primary culture.~Exclusion Criteria:~* patients did not have residual aspirated specimens for primary culture.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health with no clinically significant and relevant abnormalities of medical history or oral examination~* Participants with maxillary dental arch suitable for the retention of the palatal appliance~Exclusion Criteria:~* Participants taking fluoride supplement~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sodium fluoride (1426 ppm) (Type: EXPERIMENTAL): Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
- Sodium fluoride (1150 ppm) (Type: EXPERIMENTAL): Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
- Sodium fluoride (250 ppm) (Type: EXPERIMENTAL): Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
- Sodium fluoride (1426 ppm) + zinc base A (Type: EXPERIMENTAL): Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
- Sodium fluoride (1426 ppm) + zinc base B (Type: EXPERIMENTAL): Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
- Fluoride (0 ppm) (Type: PLACEBO_COMPARATOR): Non-zinc, 0ppm fluoride in a silica gel base

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion:~1. Patients with primary hypercholesterolemia \[Heterozygous Familial Hypercholesterolemia (heFH) or non-FH\] with moderate, high or very high CV risk and a history of statin intolerance~2. Provide signed informed consent~Exclusion:~1. Calculated serum LDL-C \<70 mg/dL (1.81 mmol/L) and very high CV risk at the screening visit~2. Calculated serum LDL-C \<100 mg/dL (2.59 mmol/L) and high or moderate CV risk at the screening visit~3. A 10-year fatal cardiovascular disease risk score \<1% at the screening visit~(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (statin rechallenge arm) (Type: OTHER): Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
- Ezetimibe (Type: ACTIVE_COMPARATOR): Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
- Alirocumab 75 mg/ up to 150 mg (Type: EXPERIMENTAL): Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cheno Effect on Transit in Health and IBS-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Healthy volunteers:~* Age (yr) 18-65~* Gender (F:M)3.5 :1~* Bowel Disease Questionnaire (BDQ) - IBS symptoms negative by Rome III criteria~* Hospital Anxiety/Depression score \<8~IBS patients:~* Age (yr) 18-65~* Gender (F:M) 5 :1~* BDQ - IBS symptoms: positive by Rome III criteria~* Hospital Anxiety/Depression score: No restrictions~Exclusion Criteria:~* Abdominal surgery (except appendectomy or cholecystectomy)~* GI medications during the 48h prior to transit measurement~* Aspartate/Alanine transaminases \>2 X Upper Limit of Normal (ULN)~* Other Medications except stable doses of estrogen, thyroid, low dose antidepressants of the dopaminergic or serotonergic class

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- NaCDC 500 mg (Type: EXPERIMENTAL): Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
- NaCDC 1000 mg (Type: EXPERIMENTAL): Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm received a placebo capsule each day for 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who show:~  * Keratoconjunctival disorder confirmed with vital dye staining~ * Abnormal Schirmer score results~Exclusion Criteria:~* Eye disease that needs therapy other than that for dry eye~* Those who need to wear contact lenses during the clinical study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- DE-089 (Type: EXPERIMENTAL): DE-089 ophthalmic solution
- HA (Type: ACTIVE_COMPARATOR): 0.1% sodium hyaluronate ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete